Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Total Assets
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) holds total assets worth $263.43 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sagimet Biosciences Inc. Series A Common Stock - Total Assets Trend (2019–2025)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Sagimet Biosciences Inc. Series A Common stock valuation for the company's overall valuation and market capitalisation.
Sagimet Biosciences Inc. Series A Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Sagimet Biosciences Inc. Series A Common Stock's total assets of $263.43 Million consist of 99.9% current assets and 0.1% non-current assets. Review Sagimet Biosciences Inc. Series A Common debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SGMT share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sagimet Biosciences Inc. Series A Common Stock's current assets represent 99.9% of total assets in 2025, an increase from 96.9% in 2019.
- Cash Position: Cash and equivalents constituted 30.1% of total assets in 2025, down from 91.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sagimet Biosciences Inc. Series A Common Stock Competitors by Total Assets
Key competitors of Sagimet Biosciences Inc. Series A Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
USA | $1.21 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Sagimet Biosciences Inc. Series A Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 45.02 | 17.55 | 24.64 |
| Quick Ratio | 45.02 | 17.55 | 24.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $238.57 Million | $119.95 Million | $73.89 Million |
Sagimet Biosciences Inc. Series A Common Stock - Advanced Valuation Insights
This section examines the relationship between Sagimet Biosciences Inc. Series A Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.60 |
| Latest Market Cap to Assets Ratio | 4.89 |
| Asset Growth Rate (YoY) | -27.3% |
| Total Assets | $116.48 Million |
| Market Capitalization | $569.10 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sagimet Biosciences Inc. Series A Common Stock's assets at a significant premium (4.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Sagimet Biosciences Inc. Series A Common Stock's assets decreased by 27.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
The table below shows the annual total assets of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $116.48 Million | -27.32% |
| 2024-12-31 | $160.26 Million | +65.70% |
| 2023-12-31 | $96.72 Million | +192.81% |
| 2022-12-31 | $33.03 Million | -44.05% |
| 2021-12-31 | $59.03 Million | -14.40% |
| 2020-12-31 | $68.96 Million | +517.91% |
| 2019-12-31 | $11.16 Million | -- |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more